The Unit includes the largest Clinical Research Center in Israel which leads and participates in multiple clinical trials in diabetes assessing glucose lowering agents including novel insulins and GLP-1 receptor agonists as well as innovative technologies for non-invasive glucose monitoring or insulin delivery. The unit collaborated with the Harvard based TIMI group in leading large international cardiovascular outcome studies in type 2 diabetes. Additionally, the unit is involved in the major studies on prevention of type 1 diabetes. Investigator initiated research on various topics including SGLT-2 inhibitors in patients with heart failure and GLP-1 receptor agonist treatment in patients with type 1 diabetes is being conducted as well.
A leading basic research laboratory is dedicated to the study of different aspects of beta-cell dysfunction in diabetes with potential implications for regenerative therapy of type 1 diabetes. Studies on the prevention of diabetic nephropathy are ongoing as well. Hadassah is affiliated with and adjacent to the Faculty of Medicine of the Hebrew University, leading to a network of successful collaborations between researchers in the Unit and leading scientists at the Hebrew University.